Revlon Second Annual Run/Walk for Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

NEW YORK-Last year, more than 20,000 people took part in the 5-kilometer Revlon Run/Walk for Women in New York City, raising more than $700,000 to fight women’s cancers. This year’s event will take place on Saturday, May 1, following a route that runs from Times Square to Central Park. The event is produced by Rehage Entertainment, Inc. and the New York Road Runners Club in cooperation with the City of New York.

NEW YORK—Last year, more than 20,000 people took part in the 5-kilometer Revlon Run/Walk for Women in New York City, raising more than $700,000 to fight women’s cancers. This year’s event will take place on Saturday, May 1, following a route that runs from Times Square to Central Park. The event is produced by Rehage Entertainment, Inc. and the New York Road Runners Club in cooperation with the City of New York.

The hotline for the event is 212-218-3327, and the website can be found at www.revlonrunwalk.com. (A similar event is being held in Los Angeles.)

The 1999 beneficiaries of the New York Run/Walk include Cancer Care, Inc., Gilda’s Club, Harlem Hospital Cancer Control Center/Patient Navigator Program, the National Breast Cancer Coalition, and the Ovarian Cancer National Alliance. The co-founders of the event are Lilly Tartikoff, widow of Brandon Tartikoff, former chairman of Paramount Pictures, who died of Hodgkin’s disease, and Ronald O. Perelman, chairman of Revlon.

Recent Videos
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Related Content